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Abstract 
Background: The development of commercially available panels for human blood plasma screening via selected 
reaction monitoring (SRM) offers reliable, cost-efficient and highly-standardized discovery and validation of protein 
biomarkers. However, protein detection by SRM can be hampered by interfering peptide fragment ions. To estimate 
the influence of interference on protein detection, we performed different types of sample preparation and imple-
mented SRM measurements for well-characterized protein targets approved by the US Food and Drug Administration.
Methods: We used the PlasmaDeepDive™ SRM assay from BiognoSYS AG for absolute quantification of 18 proteins 
in 19 samples of human plasma using three different protocols for sample preparation. SRM measurements were per-
formed using iRT standards for retention time normalization and isotopically-labeled reference peptides for absolute 
quantification. SpectroDive™ software was used for automated detection of reliable peak groups.
Results: Fourteen targeted proteins were quantitatively measured in more than half of the samples. Depletion of 
highly-abundant plasma proteins and peptide fraction clean-up on centrifuge plates resulted in detection of all 18 
targeted proteins in femtomolar to picomolar concentrations.
Conclusions: It was shown that commercially designed SRM kits are suitable for SRM detection of well-established 
plasma/serum biomarkers.
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Background
Selected Reaction Monitoring (SRM) is a targeted mass 
spectrometry method which has emerged as a promis-
ing challenger to antibody techniques of protein analy-
sis in biological samples [1]. SRM assay development is 
more cost-effective than immunoaffinity approaches. 
The process of assay development requires synthesiz-
ing analytical quantities of isotopically-labeled peptides 
and determining the unique pairs of transitions between 
parent and product ions of proteotypic peptides with the 
amino acid sequence non-recurrent in other proteins [2].
The detection method, based on triple quadrupole 
mass spectrometry, isolates the proteotypic peptide by its 
m/z and quantifies the content of fragments in a sample. 
This physical principle of signal registration of character-
istic ions’ pairs ensures high selectivity and sensitivity of 
SRM when analyzing low-abundance proteins [3]. It also 
should be noted that SRM analysis requires only a few 
microliters of blood plasma [4].
The selection of interference-free proteotypic peptides 
is the main obstacle to SRM assay development. Due to 
its technical limitations, the quadrupole mass spectrome-
ter cannot precisely isolate charged particles of particular 
m/z, which results in overlapping flows of charged parti-
cles originating from different analytes within the given 
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m/z window that cannot be resolved because of their 
similar peptidic natures [5]. This interference can distort 
mass spectrometric signatures of peptides in the complex 
matrix of a biological sample. Signal distortion hampers 
the utility of SRM measurement for quantitative analy-
sis. For example, because of interference when develop-
ing SRM assays for 1000 possible cancer protein targets, 
Huttenhain et al. could only identify a few dozen proteins 
with non-interfering proteotypic peptides in depleted 
plasma [6].
Companies specializing in the development of com-
mercial kits of peptides for SRM analysis have emerged 
in the market. Peptides not interfering with components 
of the biological matrix as well as peptides used in reten-
tion time calibration are prerequisites for commercial 
kits. Commercial kits are typically delivered with special-
ized software automating data processing such as Skyline 
(MacCoss Lab of Biological Mass Spectrometry, Univer-
sity of Washington, Seattle, WA, USA) [7], which does 
not require the studying of complex software documen-
tation and is focused on assay development and subse-
quent results analysis in “plug-and-play” mode.
In this study we used a commercially available SRM kit 
to analyze the proteotypic peptides of proteins approved 
by the US Food and Drug Administration (FDA) as 
plasma/serum biomarkers [8]. Plasma samples were pre-
pared according to different protocols in order to analyze 
the effect of sample preparation on interference of pro-
teotypic peptides.
Methods
We studied 18 proteins in 19 blood plasma samples from 
patients aged 50–70  years. The samples were obtained 
with informed consent of the patients within the frame-
work of clinical research approved by the Ethics Commit-
tee of N. N. Burdenko Neurosurgery Institute, Moscow, 
Russia.
Plasma samples were stored at −80 °C without refreez-
ing. The PlasmaDeepDive™ (BiognoSYS AG, Zurich, 
Switzerland) kit containing a mixture of isotopically-
labeled peptide standards was used to perform SRM 
measurements of 100 proteins (one proteotypic peptide 
for each protein), of which 18 were the subject matter of 
our research. The sample preparation including protein 
reduction, alkylation and tryptic cleavage was performed 
according to the PlasmaDeepDive™ kit manufacturer’s 
directions [9] using three different protocols. In the first 
protocol, crude plasma samples were subjected to tryp-
tic cleavage (Series #1). In the second protocol (Series 
#2), removal of buffer components and sample desalting 
were accomplished using centrifugal MACROSpin plates 
(Nest Group, Southborough, MA, USA). In the third pro-
tocol (Series #3), the process of depletion was carried out 
using a ProteoPrep® Immunoaffinity Albumin and IgG 
Depletion Kit (Sigma-Aldrich, St. Louis, MO, USA), fol-
lowed by trypsinolysis and peptide extraction on MAC-
ROSpin centrifuge plates.
Protein digestion was performed using trypsin (0.4 µg/
µl, Promega, Madison, WI, USA) in darkness at a tem-
perature of 37  °C for 3  h with stirring. The ratio of 
trypsin:protein was 1:100. The reaction was stopped by 
adding 20 % trifluoroacetic acid solution (Acros Organ-
ics, Morris Plains, NJ, USA), adjusting the pH of the 
peptide solution to 2.0. The trypsinolyzed plasma was 
dried, redissolved in liquid chromatography solution 
containing 0.1  % formic acid in water, and spiked with 
isotopically-labeled peptide standards from the Plas-
maDeepDive™ kit. The UltiMate® 3000 RSLCnano 
Standard LC system (Dionex, Sunnyvale, CA, USA) in 
tandem with the mass spectrometry detector TSQ Van-
tage (Thermo Scientific, Waltham, MA, USA) equipped 
with an ionization source Easy-Spray was used for chro-
matographic mass spectrometry analysis. Mobile phase 
A was 1  % acetonitrile (AcN)/0.1  % formic acid (FA)/
H2O, phase B was H2O/0.1 % FA/AcN, and the flow rate 
was 0.3 μl/min. The percentage of mobile phase B was 
increased in a gradient from 5 to 35 % over 35 min, then 
increased to 99 % in the next 5 min and maintained there 
for 10 min.
The volume of the peptide compound injection was 
3 μl, using a flow rate of 0.3 ml/min. The voltage on the 
electrode was 1900  V with the capillary temperature of 
200 °C. The impact energy values were set in accordance 
with the SRM kit preferences [9].
The raw files obtained were processed by SpectroDive™ 
and Skyline programs. Transition lists were imported 
from SpectroDive™ into Skyline to generate.sky and .skyd 
files to place into PASSEL (ID PASS00633) [10] and pro-
vide access to SRM spectra in a publicly-available format. 
Retention time recalibration using iRT-peptide [11] char-
acteristic peaks was done automatically when loading 
spectra in SpectroDive™. The quality of peptide detec-
tion was monitored by the q value calculated by mQuest/
mProphet software [12]. A peptide was considered to be 
reliably detected at a q value ≤0.01.
Results and discussion
A total of 190 SRM spectra were acquired; original raw 
files and respective transitions data in the.sky and .skyd 
format were placed in PASSEL. The spectra were allo-
cated into the three protocols of sample preparation. 
Figure  1 shows examples of SRM spectra in the Spec-
troDive™ program; Additional file  1: Figure S1 shows 
the same results in Skyline. Following the PlasmaDeep-
Dive™ protocol, three transitions per peptide were 
used for detection. Examples of peptides at different 
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concentrations ranging from 2  μM (Fig.  1a) to 1 fM 
(Fig. 1d) are given for illustration.
High intensity (1.6  ×  106, Fig.  1a) transitions of the 
target peptide registered in a biological sample showed 
some distortions where transition peaks were split. Peak 
distortion was observed for the isotopically-labeled 
standard as well. Peak distortion for an endogenous 
peptide and spike-in peptide standard was presumably 
caused by specific features of the chromatographic elu-
tion, since approximately half of the cases measuring the 
corresponding transition peaks had similar aberrations 
both for native and isotopically-labeled peptides. Despite 
imperfect chromatographic conditions, error assessment 
for this group of peaks was low (q value <10−11); there-
fore, the peptide was considered to be detected, and its 
content evaluation verifiable.
Figure  1b shows an example of unambiguous peptide 
detection. The shapes of fragment ion peaks for targeted 
and reference peptides coincide almost perfectly. In this 
case, the ratio of the transitions intensity for both the 
heavy and light peptides was maintained throughout the 
elution interval. It should be noted that in Fig.  1b, the 
ratio of the content of endogenous peptide to the refer-
ence peptide was 1:1.5, in contrast to Fig.  1a, where the 
proportion was 10:1. Another situation is presented by the 
chromatograms of peptides in low concentration (Fig. 1c), 
where the peak group for endogenous peptide was cor-
rupted due to interference. The most questionable case of 
peptide detection is shown in Fig. 1d. The intensity of tar-
geted peptide did not exceed 1500. The shaded area indi-
cates the interval in which several peaks of the two most 
intensive transitions were observed. However, the q value 
assessment for the peaks group shown in Fig. 1d still fell 
below the accepted threshold of q ≤ 0.01, which allowed 
us to consider this and a few other similar situations as 
borderline but acceptable for quantitative evaluation.
The summary of all acquired SRM spectra with q values 
≤0.01 is given in Additional file 2: Table S1. The number 
of samples in which targeted proteins (peptides) were 
detected in one, two or three technical runs was counted; 
Fig. 1 Extracted ion chromatograms of native and isotopically-labeled proteotypic peptides (marked as “NAT” and “SIS”, respectively) visualized with 
SpectroDive™ software for qualitative and quantitative analysis using three transitions per peptide: a SVLGQLGITK (Alpha 1-antitrypsin, P01009), 
high concentration; b GGYTLVSGYPK (Hemopexin, P02790), moderate concentration; c GYTQQLAFR (Complement C3, P01024), low concentration; 
d AVSPLPYLR (von Willebrand factor, P04275), in traces. Shaded zones indicate peak integration boundaries. Dashed lines mark peptide elution time 
predicted by iRT-calibration
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some examples are shown in Table 1. For example, apoli-
poprotein A1 peptide was detected in each of the 19 sam-
ples in all technical runs of each sample preparation; i.e., 
detection was observed in a total of 19 ×  3 =  57 chro-
matograms. Serum albumin was detected in 100 % of the 
cases in the first two series (i.e., in all samples in every 
technical run), while in the third series protein detection 
was achieved only in two samples and in two technical 
runs. In that same third series, von Willebrand factor was 
detected in only four samples of one technical run, and in 
two of those samples detection was reliable in two runs 
only.
Peptides of 11 FDA-approved proteins were detected in 
each sample from any of the sample preparation proto-
cols in at least two technical runs. Highly abundant pro-
teins, including the aforementioned serum albumin and 
apolipoprotein A1, but also fibrinogen α-chain, hapto-
globin and others (Additional file  2: Table S1) belonged 
to this group.
Five proteins, including insulin-like growth factor II 
and ceruloplasmin, were not detected in any of the sam-
ples in the series of experiments performed with whole 
plasma. Signatures of two other proteins, cystatin C 
and insulin-like growth factor-binding protein III, were 
detected in single samples, and in only a few cases did 
detection occur in all three technical runs. However, 
two-thirds of the targeted proteins were successfully 
detected in almost all plasma samples in three technical 
runs.
Peptide extractions done in the second series of experi-
ments allowed for detection of peptides from 17 pro-
teins (12 of them in all samples, and 11 in all technical 
runs). Compared with the first series of experiments, we 
were able to reliably detect four proteins not previously 
detected in crude plasma, including von Willebrand fac-
tor, which was detected in one of the samples in a single 
technical run.
In the third series of experiments using immunoaffinity 
depletion of highly abundant plasma proteins, we were 
able to detect all 18 protein targets. Nine proteins were 
present in all samples in every technical run, while the 
other three proteins were present in at least two techni-
cal runs in all samples. In this series, it was possible to 
detect insulin-like growth factor II not identified in the 
first two series. This protein was quantified over 16 sam-
ples; the average concentration was 6.1  ±  0.7  fM. The 
depletion procedure used in the third protocol of sample 
preparation allowed us to estimate inter-individual vari-
ation of von Willebrand factor concentration (1.15 fM, 
CV  =  59  %) in six samples. The rare detection of this 
protein is surprising given its low content in plasma, esti-
mated as 0.1 µg/ml according to published data [13].
Peptides detected in three technical runs were selected 
to assess the reproducibility of quantitative measure-
ments. The concentrations of nine out of 18 proteins 
were measured with CV <30  % between technical runs 
(Additional file 3: Figure S2). Series #1 was characterized 
by the highest reproducibility of quantification. In the 
first series, median CV was 28 %, followed by 53 and 52 % 
for Series #2 and Series #3, respectively. However, the dif-
ferences observed were not statistically significant.
Figure  2 shows target protein concentrations meas-
ured using the PlasmaDeepDive™ kit. The data were in 
the range of 31 pM (serum albumin, Series #1) to 0.1 fM 
(ceruloplasmin, Series #3). As can be seen from the box 
plot, the protein content was dependent on the sample 
preparation protocol. The difference in protein quanti-
tative assessment may be considerable; for example, for 
fibrinogen α-chain in Series #1 and Series #2, a value of 
about 1 pmol was obtained, while in Series #3, the abso-
lute concentration was ten times lower, evidently due to 
depletion.
A metaanalysis by Polanski and Anderson [14] pro-
vides data on plasma protein content, where different 
Fig. 2 Box plot for concentrations of FDA-approved proteins averaged across three technical runs and 19 plasma samples using three protocols of 
sample preparation (Series #1–3)
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immunoaffinity approaches were used to determine 
protein concentrations. We compared the results of our 
Series #3 experiment with the data from this study [14]. 
The coefficient of determination in double logarithmic 
coordinates was 0.80. This high value is due to the pres-
ence of two groups of high- and average-abundance 
proteins. Significant correlations were not observed in 
the group of high-abundance proteins (Additional file 4: 
Figure S3).
Conclusions
FDA-approved plasma biomarkers are feasible for SRM 
detection using commercially available SRM assay kits. 
Detection of 18 targets required analysis of 19 samples to 
acquire reproducible SRM spectra. It was observed that 
even a rigorously optimized kit suffers from interference 
in some cases. In this regard, application of isotopically-
labeled peptides and retention time standards is essential 
to assure that SRM measurements are resistant to chro-
matographic distortions.
Extensive sample preparation enabled detection of 
peptide concentrations in a range covering five orders of 
magnitude. In a series using crude plasma five proteins 
remained undetected, while application of clean-up and 
depletion strategies reduced the number of undetected 
proteins to one and zero, respectively.
Despite the fact that the overall correlation of our 
results with published plasma protein data was high, 
the results of SRM measurements for particular pro-
teins differed by the orders of magnitude. Therefore, 
it is necessary to validate the SRM results by selecting 
reference points across the concentration range [15].
Finally, integrated SpectroDive™ software, optimized 
for a particular assay, provides user serviceability in mass 
spectra signal processing and data analysis and allows 
permanent inner control of retention time for peptide 
fragments under test.
Additional files
Additional file 1: Figure S1. Extracted ion chromatograms of native 
and isotopically labelled proteotypic peptides (marked as “NAT” and “SIS”, 
respectively) obtained with Skyline software for the peptides of Plas-
maDeepDive™ kit in Series #3: а SVLGQLGITK (Alpha 1-antitrypsin, P01009), 
1592 fM; b GGYTLVSGYPK (Hemopexin, P02790), 475 fM; c GYTQQLAFR 
(Complement C3, P01024), 22 fM; d AVSPLPYLR (von Willebrand factor, 
P04275), 2 fM. Dashed lines indicate peak integration boundaries.
Additional file 2: Table S1. The summary of all obtained SRM spectra 
with q-values ≤ 0.01.
Additional file 3: Figure S2. Mean values of the coefficient of variation 
among technical runs in different series of measurement. Each point cor-
responds to the proteins detected in three technical runs (nine proteins in 
Series #1 and Series #3, and 11 proteins in Series #2).
Additional file 4: Figure S3. Comparison between protein concentra-
tion measured by SRM (Series #3) and by other approaches [14].
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